Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (238)

« Back to Publications

High-throughput monoclonal gammopathy community monitoring programme.

Agarwal G. et al, (2026), Br J Haematol

Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

Vijjhalwar R. et al, (2026), Osteoporos Int

SECURE study: Incidentally detected MGUS patients have comparable depression and anxiety rates to UK general population.

Knight ES. et al, (2026), Br J Haematol, 208, 325 - 328

High-risk smoldering myeloma - a case for early intervention?

Krishnamoorthi A. et al, (2025), Curr Opin Oncol, 37, 650 - 657

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

Agarwal G. et al, (2025), Br J Haematol, 207, 2167 - 2172

Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study.

Choi S. et al, (2025), Blood Cancer J, 15

Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma.

Knop S. et al, (2025), J Patient Rep Outcomes, 9

Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.

Terpos E. et al, (2025), Am J Hematol, 100, 1839 - 1850

Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death

Watson ECR. et al, (2025)

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis.

Fieggen J. et al, (2025), Blood Adv, 9, 3766 - 3770

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.

Tsang C. et al, (2025), BMC Cancer, 25

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.

Kannan A. et al, (2025), Blood Rev, 72

pproaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?

Vijjhalwar R. et al, (2025), Indian J Hematol Blood Transfus, 41, 478 - 493

Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland.

Watson ECR. et al, (2025), EJHaem, 6

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Perrot A. et al, (2025), Eur J Haematol, 114, 883 - 889

Load More

1
2
3
4
5
6
7
...
»